Health
Secukinumab Has High Retention Rate in Real-World Psoriatic Arthritis Study – AJMC.com Managed Markets Network
New real-world data shows 64% of patients with psoriatic arthritis who had previously been on a biologic stayed on secukinumab for the duration of the study.
A new study suggests secukinumab (Cosenytx) has a high retention rate among biologic-experienced patients with psoriatic arthritis (PsA) in real-world settings, and also produces minimal serious side effects.
The research is important because previous data on the real-world usage of the recombinant human monoclonal antibody has been scarce. The drug, which targets interleukin-17A, has been approved for the treatment of PsA since 2015 in Europe and 2016 in the United States.
A team of Greek inv…
-
Business17 hours ago10 ASX shares to buy after the market selloff
-
General20 hours ago‘We are here for you’: PM to bring help to flood zones
-
Business16 hours ago$10,000 invested in ANZ shares 5 years ago is now worth…
-
General19 hours agoWe’ve all talked about potential economic consequences for Australia of Trump’s policies. Now they’re happening